Any current/future new fundraising through debt or equity?

Sai Life Sciences plans to fund its FY27 capex of INR1,100 to 1,300 crores through a mix of internal accruals and debt. No specific details or amounts regarding new debt issuance have been disclosed. The company expects its debt-to-EBITDA ratio to remain healthy despite increased capex and possible debt. There is no mention of any planned equity fundraising in the provided excerpts. Capex is primarily for capacity expansion and capability building, including CDMO and CRO segments. The company will continue to calibrate the pace and phasing of investments based on evolving business conditions a

Any current/future capex/capital investment/strategic investment?

FY27 capex guidance: INR 1,100 crores to INR 1,300 crores, funded via internal accruals and debt. Capex split: 75% towards capacity expansion (including 700 KL to 1,150 KL plant expansion and doubling process R&D capacity), 25% towards capability building and AI/digital technology. Brownfield expansions expected to take 12-18 months; greenfield sites may take 24-30 months. Peptide and ADC development capabilities are part of the current capex. Investments driven by clear demand visibility and strategic conversations with large pharma clients. AI/digital transformation investment includes intan

Future growth expectations in sales/revenue/volumes?

Sai Life Sciences expects a revenue CAGR of 15% to 20% from the current run rate (~INR 2,200 crores). Growth in the short term will likely be driven by pharma clients, with biotech contributions expected to return to a balanced 50/50 mix long-term. CDMO segment showed strong 30%+ growth in FY26; growth outlook for FY27 and FY28 remains strong. Increased capex (~INR 1,100-1,300 crores) focused on capacity expansion (75%) and capability/technology (25%) to support volume growth. Revenue visibility has improved through long-term collaborations and added large pharma customers. Long-term volume gr

Future growth expectations in earnings/operating earnings/profits/EPS?

Sai Life Sciences projects revenue CAGR of 15% to 20% over the next few years. EBITDA margins are targeted to be maintained in the steady-state range of 28% to 30% within a 2-3 year timeframe. The company expects some short-term dips in asset turnover due to accelerated capex but aims for a medium-term asset turn of 1.2 to 1.4 times. Capex of INR1,100 to 1,300 crores is planned for fiscal 2027, focused on capacity expansion (75%) and capability/technology upgrades (25%). FY27 second half is expected to be stronger than the first half, reflecting growth ramp-up. Profit after tax (PAT) growth wa

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the exact current or expected order book or pending orders in terms of value or volume. However, it indicates strong visibility and confidence into FY27 growth based on customer conversations. The company has seen increased late-stage and mid-stage development outsourcing from large pharma, enhancing pipeline visibility. Customers are providing better visibility of their pipelines, indicating more programs likely to translate into commercial manufacturing within 12-15 months. The company has added multiple new commercial molecules and Phase III/pre-re

IN US

Sale is live|00:00:00left today

Sai Life Sciences LtdQ1 FY26Pharmaceuticals & Biotechnology

Sai Life Sciences Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,205P/E: 65.1Market Cap: ₹23.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Sai Life Sciences expects a revenue CAGR of 15% to 20% from the current run rate (~INR 2,200 crores).
→Growth in the short term will likely be driven by pharma clients, with biotech contributions expected to return to a balanced 50/50 mix long-term.
→CDMO segment showed strong 30%+ growth in FY26; growth outlook for FY27 and FY28 remains strong.
→Increased capex (~INR 1,100-1,300 crores) focused on capacity expansion (75%) and capability/technology (25%) to support volume growth.
→Revenue visibility has improved through long-term collaborations and added large pharma customers.
→Long-term volume growth will be enabled by expanding discovery, development, and commercial manufacturing capabilities.
→Biotech funding recovery and strategic pharma outsourcing expected to support sustained growth.
→Expect a stronger second half in FY27, guided by phasing of new capacity and commercial product ramp-up.

Margin guidance

Category 3

→Sai Life Sciences projects revenue CAGR of 15% to 20% over the next few years.
→EBITDA margins are targeted to be maintained in the steady-state range of 28% to 30% within a 2-3 year timeframe.
→The company expects some short-term dips in asset turnover due to accelerated capex but aims for a medium-term asset turn of 1.2 to 1.4 times.
→Capex of INR1,100 to 1,300 crores is planned for fiscal 2027, focused on capacity expansion (75%) and capability/technology upgrades (25%).
→FY27 second half is expected to be stronger than the first half, reflecting growth ramp-up.
→Profit after tax (PAT) growth was over 100% in fiscal 2026, indicating strong earnings momentum.
→Long-term outlook remains strong, driven by pharma-led growth and balanced pharma/biotech revenue mix targeting 50/50 split.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Sai Life Sciences plans to fund its FY27 capex of INR1,100 to 1,300 crores through a mix of internal accruals and debt.
→No specific details or amounts regarding new debt issuance have been disclosed.
→The company expects its debt-to-EBITDA ratio to remain healthy despite increased capex and possible debt.
→There is no mention of any planned equity fundraising in the provided excerpts.
→Capex is primarily for capacity expansion and capability building, including CDMO and CRO segments.
→The company will continue to calibrate the pace and phasing of investments based on evolving business conditions and customer demand.

Order book

→The transcript does not explicitly mention the exact current or expected order book or pending orders in terms of value or volume.
→However, it indicates strong visibility and confidence into FY27 growth based on customer conversations.
→The company has seen increased late-stage and mid-stage development outsourcing from large pharma, enhancing pipeline visibility.
→Customers are providing better visibility of their pipelines, indicating more programs likely to translate into commercial manufacturing within 12-15 months.
→The company has added multiple new commercial molecules and Phase III/pre-registration molecules, suggesting a healthy and expanding order pipeline.
→Integrated CDMO and CRO engagements with large pharma and biotech customers are increasing, supporting a robust demand outlook.
→Overall, while exact order book figures are not stated, the company expresses optimism based on long-term strategic partnerships and expanding capacity.

Capex plans

Yes

→FY27 capex guidance: INR 1,100 crores to INR 1,300 crores, funded via internal accruals and debt.
→Capex split: 75% towards capacity expansion (including 700 KL to 1,150 KL plant expansion and doubling process R&D capacity), 25% towards capability building and AI/digital technology.
→Brownfield expansions expected to take 12-18 months; greenfield sites may take 24-30 months.
→Peptide and ADC development capabilities are part of the current capex.
→Investments driven by clear demand visibility and strategic conversations with large pharma clients.
→AI/digital transformation investment includes intangible software/tools aiming to enhance productivity and data integration.
→Capex for new site expected to start late FY27 or early FY28.
→Capex approach is science-led, emphasizing flexibility and high long-term returns rather than capacity-heavy expansion.

How does Sai Life Sciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Sai Life Sciences Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Sai Life Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio